The stock of MBX Biosciences Inc (MBX) has seen a 10.45% increase in the past week, with a -8.71% drop in the past month, and a 78.91% flourish in the past quarter. The volatility ratio for the week is 9.87%, and the volatility levels for the past 30 days are at 9.80% for MBX. The simple moving average for the last 20 days is 12.73% for MBX stock, with a simple moving average of -14.51% for the last 200 days.
Is It Worth Investing in MBX Biosciences Inc (NASDAQ: MBX) Right Now?
There are mixed opinions on the stock, with 3 analysts rating it as a “buy”, 2 rating it as “overweight”, 0 rating it as “hold”, and 0 rating it as “sell”.
The public float for MBX is 14.84M and currently, short sellers hold a 31.35% ratio of that float. The average trading volume of MBX on July 04, 2025 was 320.06K shares.
MBX stock’s latest price update
MBX Biosciences Inc (NASDAQ: MBX)’s stock price has plunge by 1.14%relation to previous closing price of $12.33. Nevertheless, the company has seen a 10.45% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-23 that CARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Andreas Moraitis, M.D.
Analysts’ Opinion of MBX
Many brokerage firms have already submitted their reports for MBX stocks, with Citizens JMP repeating the rating for MBX by listing it as a “Mkt Outperform”. The predicted price for MBX in the upcoming period, according to Citizens JMP is $38 based on the research report published on April 10, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see MBX reach a price target of $40. The rating they have provided for MBX stocks is “Buy” according to the report published on October 08th, 2024.
Jefferies gave a rating of “Buy” to MBX, setting the target price at $35 in the report published on October 08th of the previous year.
MBX Trading at 10.61% from the 50-Day Moving Average
After a stumble in the market that brought MBX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.65% of loss for the given period.
Volatility was left at 9.80%, however, over the last 30 days, the volatility rate increased by 9.87%, as shares sank -8.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +44.33% upper at present.
During the last 5 trading sessions, MBX rose by +10.45%, which changed the moving average for the period of 200-days by -47.27% in comparison to the 20-day moving average, which settled at $11.06. In addition, MBX Biosciences Inc saw N/A in overturn over a single year, with a tendency to cut further N/A.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MBX starting from Pescovitz Ora H., who purchase 7,693 shares at the price of $5.89 back on Apr 08 ’25. After this action, Pescovitz Ora H. now owns 24,329 shares of MBX Biosciences Inc, valued at $45,312 using the latest closing price.
GORDON CARL L, the Director of MBX Biosciences Inc, purchase 143,170 shares at $10.84 during a trade that took place back on Feb 18 ’25, which means that GORDON CARL L is holding 3,255,000 shares at $1,551,963 based on the most recent closing price.
Stock Fundamentals for MBX
The total capital return value is set at -0.35%. Equity return is now at value -48.22%, with -45.74% for asset returns.
Based on MBX Biosciences Inc (MBX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -512.68.
Currently, EBITDA for the company is -67.95 million with net debt to EBITDA at 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 23.31.
Conclusion
In conclusion, MBX Biosciences Inc (MBX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
